Cardinal Health, Henry Schein Ink Long-Term Deal To Serve Physician Offices

Healthcare services company Cardinal Health, Inc. (CAH) and Henry Schein, Inc. (HSIC) have signed a long-term strategic agreement to provide one of the most comprehensive service and product offerings to office-based medical practices. This deal combines Cardinal Health's product line and extensive touch points across the health system with Henry Schein's outstanding service capabilities and history in serving office-based practices.

Pursuant to the agreement, the physician office-focused commercial organization of Cardinal Health's Medical unit would be consolidated into the commercial organization of Henry Schein's Medical Group. Henry Schein has committed to buy Cardinal Health Brand products and utilize Cardinal Health as a primary source for various medical products. The transaction is expected to be slightly accretive to both the companies' respective earnings per share in fiscal 2015 and increasingly accretive thereafter.

The physician office sales team and physician office distribution business of Cardinal Health's Medical segment, with annual sales exceeding $300 million, would be transitioned into Henry Schein's Medical Group. Cardinal Health would transition to Henry Schein the servicing of the medical product needs of over 25,000 physician office customer locations and nearly 200 employees.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The 737 MAX 10, Boeing Co.'s largest 737 Max model, is taking its maiden flight today, reports said citing people familiar with the matter. The flight after months of testing and certification will be around 10 a.m. local time from the Seattle area. The schedule could change depending on weather or other factors. Meanwhile, the jetliner is expected to enter commercial service in 2023. Medical devices supplier Smiths Medical, affiliated to Smiths Group plc, is recalling certain Jelco Hypodermic Needle-Pro Fixed Needle insulin syringes with skewed graduation markings, the U.S. Food and Drug Administration said. The recall was initiated after the company became aware of specific models and lots of Jelco insulin syringes that may exhibit skewed odd number line graduation markings. Saliva-based COVID-19 testing is rolled out as a pilot for public schools in New York City. The new two-month pilot program is being implemented in about 50 New York City public schools and utilizes Fluidigm Technology to offer RT-PCR COVID-19 testing. New York City public schools have instituted mandatory random weekly testing in all reopened school buildings to ensure safer in-person learning.
Follow RTT